Your browser doesn't support javascript.
loading
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Tutt, Andrew; Tovey, Holly; Cheang, Maggie Chon U; Kernaghan, Sarah; Kilburn, Lucy; Gazinska, Patrycja; Owen, Julie; Abraham, Jacinta; Barrett, Sophie; Barrett-Lee, Peter; Brown, Robert; Chan, Stephen; Dowsett, Mitchell; Flanagan, James M; Fox, Lisa; Grigoriadis, Anita; Gutin, Alexander; Harper-Wynne, Catherine; Hatton, Matthew Q; Hoadley, Katherine A; Parikh, Jyoti; Parker, Peter; Perou, Charles M; Roylance, Rebecca; Shah, Vandna; Shaw, Adam; Smith, Ian E; Timms, Kirsten M; Wardley, Andrew M; Wilson, Gregory; Gillett, Cheryl; Lanchbury, Jerry S; Ashworth, Alan; Rahman, Nazneen; Harries, Mark; Ellis, Paul; Pinder, Sarah E; Bliss, Judith M.
Afiliación
  • Tutt A; Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK. andrew.tutt@icr.ac.uk.
  • Tovey H; Breast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, Guy's Hospital, London, UK. andrew.tutt@icr.ac.uk.
  • Cheang MCU; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.
  • Kernaghan S; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.
  • Kilburn L; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.
  • Gazinska P; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.
  • Owen J; Breast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, Guy's Hospital, London, UK.
  • Abraham J; King's Health Partners Cancer Biobank, King's College London, London, UK.
  • Barrett S; Velindre Cancer Centre, Cardiff, UK.
  • Barrett-Lee P; Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Brown R; Velindre Cancer Centre, Cardiff, UK.
  • Chan S; Department of Surgery and Cancer, Imperial College London, London, UK.
  • Dowsett M; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
  • Flanagan JM; Department of Clinical Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Fox L; Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK.
  • Grigoriadis A; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, UK.
  • Gutin A; Department of Surgery and Cancer, Imperial College London, London, UK.
  • Harper-Wynne C; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.
  • Hatton MQ; Breast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, Guy's Hospital, London, UK.
  • Hoadley KA; Myriad Genetics, Inc., Salt Lake City, UT, USA.
  • Parikh J; Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust, Kent, UK.
  • Parker P; Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK.
  • Perou CM; Department of Genetics and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Roylance R; Department of Radiology, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, UK.
  • Shah V; School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Medical School Campus, London, UK.
  • Shaw A; Protein Phosphorylation Laboratory, Francis Crick Institute, London, UK.
  • Smith IE; Department of Genetics and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Timms KM; Department of Oncology, University College London Hospitals NHS Foundation Trust and NIHR University College London Hospitals Biomedical Research Centre, London, UK.
  • Wardley AM; Breast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, Guy's Hospital, London, UK.
  • Wilson G; Department of Medical and Molecular Genetics, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Gillett C; Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Lanchbury JS; Myriad Genetics, Inc., Salt Lake City, UT, USA.
  • Ashworth A; NIHR Manchester Clinical Research Facility at The Christie and Division of Cancer Sciences and University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
  • Rahman N; The Christie NHS Foundation Trust, Manchester, UK.
  • Harries M; King's Health Partners Cancer Biobank, King's College London, London, UK.
  • Ellis P; Research Oncology, Division of Cancer Studies, King's College London, Guy's Hospital, London, UK.
  • Pinder SE; Myriad Genetics, Inc., Salt Lake City, UT, USA.
  • Bliss JM; UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, USA.
Nat Med ; 24(5): 628-637, 2018 05.
Article en En | MEDLINE | ID: mdl-29713086
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carboplatino / Proteína BRCA1 / Proteína BRCA2 / Neoplasias de la Mama Triple Negativas / Mutación Tipo de estudio: Clinical_trials / Guideline Límite: Female / Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carboplatino / Proteína BRCA1 / Proteína BRCA2 / Neoplasias de la Mama Triple Negativas / Mutación Tipo de estudio: Clinical_trials / Guideline Límite: Female / Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido